Skip to main content
Premium Trial:

Request an Annual Quote

Penn State Hershey Children's Hospital, Serametrix Collaborate on CDx for Brain Cancer

NEW YORK (GenomeWeb News) – Penn State Hershey Children's Hospital and Serametrix today announced a collaboration to develop a companion diagnostic test for predicting patient response to a novel immunotherapy for brain cancer.

The deal is part of the Pediatric Cancer Immunotherapy Program at the hospital, which provides therapies aimed at children with relapsed tumors. The hospital has novel immune-based therapies for pediatric patients with relapsed neuroblastoma and sarcoma, and as part of the collaboration Serametrix will analyze about 100 samples from patients enrolled in trials for the therapies during the next year, the partners said.

Financial and other terms of the deal were not disclosed.

Based in Carlsbad, Calif., Serametrix develops technologies to detect changes in serum for personalized medicine-based approaches. The firm said it has identified tumor antigen panels for predicting clinical response in cancer types, including melanoma, colorectal cancer, breast cancer, and glioblastoma.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.